Aspirin (Ecospirin) for Cardiovascular and Cerebrovascular Prevention
Ecospirin contains acetylsalicylic acid (aspirin) and is an antiplatelet agent. [1] Aspirin use is clearly indicated for secondary prevention in patients with established atherosclerotic cardiovascular disease (ASCVD). [2]
Absolute Indications for Use (Secondary Prevention)
Aspirin is recommended in patients with coronary artery disease unless contraindicated. [2]
Aspirin is recommended for history of myocardial infarction to reduce risk of subsequent events. [1]
Aspirin is recommended for ischemic stroke to prevent subsequent cardiovascular events and death. [1]
Aspirin is recommended for transient ischemic attack (TIA) (mini-strokes) to prevent subsequent cardiovascular events and death. [1]
Aspirin is recommended for established vascular disease (other atherosclerotic conditions within secondary prevention) unless contraindicated. [2]
Absolute Indications for Primary Prevention (Net Benefit-Based)
Initiation of low-dose aspirin for primary prevention is generally not recommended for adults older than 70 years due to bleeding risk outweighing benefit. [3]
Initiation of low-dose aspirin for primary prevention is generally reserved for select higher-risk patients and balanced against bleeding risk, not used routinely. [4]
Initiation Thresholds That Convert Primary Prevention From “Possible” to “Not Recommended”
Aspirin for primary prevention is recommended against as a routine preventive strategy in older adults because net benefit is not favorable in that age range. [3]
Primary prevention decisions should incorporate both baseline cardiovascular risk and bleeding risk due to the small net benefit in the USPSTF framework. [3]
Contraindications That Eliminate “Absolute Indication”
Aspirin should be avoided when contraindicated due to bleeding risk concerns, including situations where aspirin is not the best treatment option for the clinical context. [1]
Management Nuances Affecting “Absolute Indication”
Aspirin benefit is established for patients with prior cardiovascular or cerebrovascular events in modern evidence summaries. [5]
Aspirin selection for secondary prevention should occur within guideline-directed antiplatelet strategies and continued indefinite therapy when appropriate unless contraindicated. [2]